Cited by 915Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Open access

Azzoli, Christopher G., Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H., Laskin, Janessa L., Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pfister, David G., Piantadosi, Steven, Schiller, Joan H., Smith, Reily, Smith, Thomas J., Strawn, John R., Trent, David, Giaccone, Giuseppe·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2009.23.5622PMC PMC2793036

Open this paper in CoChat — free account

Abstract

The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that improve overall survival. Treatments that improve only progression-free survival prompted scrutiny of toxicity and quality of life. For first-line therapy in patients with performance status of 0 or 1, a platinum-based two-drug combination of cytotoxic drugs is recommended. Nonplatinum cytotoxic doublets are acceptable for patients with contraindications to platinum therapy. For patients with performance status of 2, a single cytotoxic drug is sufficient. Stop first-line cytotoxic chemotherapy at disease progression or after four cycles in patients who are not responding to treatment. Stop two-drug cytotoxic chemotherapy at six cycles even in patients who are responding to therapy. The first-line use of gefitinib may be recommended for patients with known epidermal growth factor receptor (EGFR) mutation; for negative or unknown EGFR mutation status, cytotoxic chemotherapy is preferred. Bevacizumab is recommended with carboplatin-paclitaxel, except for patients with certain clinical characteristics. Cetuximab is recommended with cisplatin-vinorelbine for patients with EGFR-positive tumors by immunohistochemistry. Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy. Erlotinib is recommended as third-line therapy for patients who have not received prior erlotinib or gefitinib. Data are insufficient to recommend the routine third-line use of cytotoxic drugs. Data are insufficient to recommend routine use of molecular markers to select chemotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.23.5622

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655

Flagged first, then by citations

Show all 218 references

2 of the 218 references couldn’t be matched to a known paper.

Research works printed but not linked: 7

10.1200/jco.2002.20.5.1335 · DOI
Lynch TJ, Presented at the 12th World Conference on Lung Cancer
Lord RV, 2002, Clin Cancer Res, 8, 2286
Mihaylova Z, 2007, J BUON, 12, 105
Langer CJ, 2004, Oncology, 18, 17
Brose MS, 2002, Cancer Res, 62, 6997
Suzuki Y, 1990, Oncogene, 5, 1037

Sorted by citations

Items 101–200 of 911

Feasibility of Image-Guided Transthoracic Core-Needle Biopsy in the BATTLE Lung Trial
Tam, A. L., Kim, E. S., Lee, J. J., Ensor, J., Hicks, M. E., Tang, X., Blumenschein, G. R., Alden, C. M., Erasmus, J. J., Tsao, A. S., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318287c91e · Cited by 92
Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting
Abernethy, A. P., Arunachalam, A., Burke, T. A., McKay, C., Cao, X., Sorg, R. A., & Carbone, D. P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178420 · Cited by 93
CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor T-cell responses
Cheng, H., Onder, L., Cupovic, J., Boesch, M., Novković, M., Pikor, N. B., Tarantino, I., Rodriguez, R., Schneider, T., Jochum, W., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.12.998 · Cited by 89
CircRNAs and lung cancer: Biomarkers and master regulators
Di, X., Jin, X., Li, R., Zhao, M., & Wang, K. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.01.055 · Cited by 89
The role of combination chemo-immunotherapy in advanced non-small cell lung cancer
Rocco, D., Gravara, L. D., Battiloro, C., & Gridelli, C. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1631800 · Cited by 89
ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development
Scagliotti, G. V., Stahel, R. A., Rosell, R., Thatcher, N., & Soria, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.001 · Cited by 90
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial
Kubota, K., Sakai, H., Katakami, N., Nishio, M., Inoue, A., Okamoto, H., Isobe, H., Kunitoh, H., Takiguchi, Y., Kobayashi, K., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv190 · Cited by 89
Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells
Circu, M. L., Cardelli, J. A., Barr, M. P., O'Byrne, K. J., Mills, G. M., & El-Osta, H. E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184922 · Cited by 93
Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin
Guo, S., Zhang, Y., Wu, Z., Zhang, L., He, D., Li, X., & Wang, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109225 · Cited by 88
The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer
Arrieta, O. G., Cardona, A. F., Corrales, L., Campos-Parra, A. D., Sánchez-Reyes, R., Amieva-Rivera, E., Rodríguez, J. K., Vargas, C. A., Carranza, H., Otero, J. M., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.12.009 · Cited by 88
Combination lung cancer chemotherapy: Design of a pH-sensitive transferrin-PEG-Hz-lipid conjugate for the co-delivery of docetaxel and baicalin
Li, S., Wang, L., Li, N., Liu, Y., & Su, H. C. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.090 · Cited by 85
TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer
Xu, W., Wang, S., Chen, Q., Zhang, Y., Ni, P., Wu, X., Zhang, J., Qiang, F., Li, A., Røe, O. D., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.27 · Cited by 85
Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
Hayashi, H., Okamoto, I., Morita, S., Taguri, M., & Nakagawa, K. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr487 · Cited by 84
Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
Domvri, K., Zarogoulidis, P., Darwiche, K., Browning, R. F., Jr., Li, Q., Turner, J. F., Kioumis, I. P., Spyratos, D., Porpodis, Κ., Papaiwannou, A., et al. (2013) · Journal of Cancer · doi:10.7150/jca.7734 · Cited by 82
Projecting future drug expenditures—2012
Hoffman, J. M., Li, E., Doloresco, F., Matusiak, L. M., Hunkler, R. J., Shah, N. D., Vermeulen, L. C., & Schumock, G. T. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110697 · Cited by 81
Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer
Fujimoto, D., Kato, R., Morimoto, T., Shimizu, R., Sato, Y., Kogo, M., Ito, J., Teraoka, S., Nagata, K., Nakagawa, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168465 · Cited by 79
Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer
Lee, K. H., Lee, J. S., Kim, S., Pereira, J. R., Han, B., Song, X., Wang, J., Kim, H.-K., Sahoo, T. P., Digumarti, R., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.035 · Cited by 79
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials
Qi, W., Sun, Y., Shen, Z., & Yao, Y. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000189 · Cited by 76
Cytology Smears in the Era of Molecular Biomarkers in Non–Small Cell Lung Cancer: Doing More With Less
Lozano, M. D., Echeveste, J. I., Abengozar‐Muela, M., Mejías, L. D., Idoate, M. A., Calvo, A., & de Andrea, C. E. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0208-ra · Cited by 76
PAQR4 promotes chemoresistance in non-small cell lung cancer through inhibiting Nrf2 protein degradation
Xu, P., Jiang, L., Yang, Y., Wu, M., Liu, B., Shi, Y., Shen, Q., Jiang, X., He, Y., Cheng, D., et al. (2020) · Theranostics · doi:10.7150/thno.43142 · Cited by 74
Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome
Shepherd, F. A., Douillard, J., & Blumenschein, G. R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822e28fc · Cited by 74
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin
on behalf of Bio-FAST trial group, Tiseo, M., Bordi, P., Bortesi, B., Boni, L., Boni, C., Baldini, E., Grossi, F., Recchia, F., Zanelli, F., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.127 · Cited by 73
Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor
Kuo, K.-T., Huang, W.-C., Bamodu, O. A., Lee, W., Wang, C., Hsiao, M., Wang, L.-S., & Yeh, C. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0533-9 · Cited by 73
Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma
Wangari‐Talbot, J., & Hopper-Borge, E. A. (2013) · Journal of cancer research updates · doi:10.6000/1929-2279.2013.02.04.5 · Cited by 80
Maintenance Therapy With Continuous or Switch Strategy in Advanced Non-small Cell Lung Cancer
Zhang, X., Zang, J., Xu, J., Bai, C., Qin, Y., Liu, K., Wu, C., Wu, M., He, Q., Zhang, S., et al. (2011) · Chest · doi:10.1378/chest.10-2745 · Cited by 71
Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives
Tang, J., Salama, R., Gadgeel, S. M., Sarkar, F. H., & Ahmad, A. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00015 · Cited by 73
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Azzoli, C. G., Temin, S., & Giaccone, G. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2011.000374 · Cited by 71
Self-citation
Clinical Practice Guidelines and Consensus Statements in Oncology – An Assessment of Their Methodological Quality
Jacobs, C. M., Graham, I. D., Makarski, J., Chassé, M., Fergusson, D. A., Hutton, B., & Clemons, M. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110469 · Cited by 70
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
Gridelli, C., Ardizzoni, A., Douillard, J., Hanna, N. H., Manegold, C., Perrone, F., Pirker, R., Rosell, R., Shepherd, F. A., Petris, L. D., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.11.018 · Cited by 70
Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer
Salloum, R. G., Smith, T. J., Jensen, G. A., & Lafata, J. E. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.07.005 · Cited by 70
Self-citation
Improving Access to Cancer Treatments: The Role of Biosimilars
Chopra, R., & Lopes, G. D. L., Jr. (2017) · Journal of Global Oncology · doi:10.1200/jgo.2016.008607 · Cited by 70
Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
Isobe, K., Hata, Y., Tochigi, N., Kaburaki, K., Kobayashi, H., Makino, T., Otsuka, H., Sato, F., Ishida, F., Kikuchi, N., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000125 · Cited by 70
Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease
Kenmotsu, H., Naito, T., Mori, K. P., Ko, R., Ono, A., Wakuda, K., Imai, H., Taira, T., Murakami, H., Endo, M., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2670-y · Cited by 68
Afatinib (BIBW 2992) Development in Non-Small-Cell Lung Cancer
Hirsh, V. (2011) · Future Oncology · doi:10.2217/fon.11.62 · Cited by 69
Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy
Ito, Y., Karayama, M., Inui, N., Kuroishi, S., Nakano, H., Nakamura, Y., Yokomura, K., Toyoshima, M., Shirai, T., Masuda, M., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.017 · Cited by 69
Prognostic Role of ERCC1 in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Roth, J. A., & Carlson, J. J. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.04.005 · Cited by 68
The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma
Betz, B. L., Dixon, C. A., Weigelin, H. C., Knoepp, S. M., & Roh, M. H. (2013) · Cancer Cytopathology · doi:10.1002/cncy.21286 · Cited by 68
Strategies for Prolonged Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
Fidias, P. M., & Novello, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7074 · Cited by 67
Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial
Galetta, D., Cinieri, S., Pisconti, S., Gebbia, V., Morabito, A., Borsellino, N., Maiello, E., Febbraro, A., Catino, A., Rizzo, P., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.002 · Cited by 67
Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis
Li, J., Chen, R., Ji, M. Q., Zou, S., & Zhu, L.-N. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2804-x · Cited by 68
Toll-like receptor agonists: a patent review (2011 - 2013)
Hussein, W. M., Liu, T.-Y., Skwarczynski, M., & Toth, I. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.880691 · Cited by 68
Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer
Pujol, J.-L., Pirker, R., Lynch, T. J., Butts, C. A., Rosell, R., Shepherd, F. A., Vansteenkiste, J., O'Byrne, K. J., de Blas, B., Heighway, J., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.006 · Cited by 66
MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancer
Shen, H., Wang, L., Ge, X. Q., Jiang, C., Shi, Z., Li, D., Liu, W., Yu, X., & Shu, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.8011 · Cited by 66
DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile
Hermans, B. C. M., Derks, J. L., Thunnissen, E., van Suylen, R. J., den Bakker, M. A., Groen, H. J. M., Smit, E. F., Damhuis, R. A. M., van den Broek, E. C., Rüland, A., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.010 · Cited by 66
Lung cancer chemotherapy using nanoparticles: Enhanced target ability of redox-responsive and pH-sensitive cisplatin prodrug and paclitaxel
Wang, B., Hu, W., Yan, H., Chen, G., Zhang, Y., Mao, J., & Wang, L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111249 · Cited by 66
Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer
Tan, E.-H., Goss, G. D., Salgia, R., Besse, B., Gandara, D. R., Hanna, N. H., Yang, J. C., Thertulien, R., Wertheim, M. S., Mazières, J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318220c93e · Cited by 66
SOX30 Inhibits Tumor Metastasis through Attenuating Wnt-Signaling via Transcriptional and Posttranslational Regulation of β-Catenin in Lung Cancer
Han, F., Liu, W., Shi, X., Yang, J., Zhang, X., Li, Z., JIANG, X. H., Li, Y., Li, J., Huang, C., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.026 · Cited by 66
The Victorian Lung Cancer Registry Pilot: Improving the Quality of Lung Cancer Care Through the Use of a Disease Quality Registry
Stirling, R. G., Evans, S., McLaughlin, P., Senthuren, M., Millar, J. L., Gooi, J. H., Irving, L. B., Mitchell, P., Haydon, A. M., Ruben, J., et al. (2014) · Lung · doi:10.1007/s00408-014-9603-8 · Cited by 66
Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian in Phase II and III Clinical Trials
Hasegawa, Y., Kawaguchi, T., Kubo, A., Ando, M., Shiraishi, J., Isa, S., Tsuji, T., Tsujino, K., Ou, S. I., Nakagawa, K., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822722b6 · Cited by 67
Progress in Standard of Care Therapy and Modest Survival Benefits in the Treatment of Non-small Cell Lung Cancer Patients in the Netherlands in the Last 20 Years
van der Drift, M. A., Karim‐Kos, H. E., Siesling, S., Groen, H. J. M., Wouters, M. W. J. M., Coebergh, J. W. W., de Vries, E., & Janssen-Heijnen, M. L. G. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823a01fb · Cited by 64
Nanomedicines guided nanoimaging probes and nanotherapeutics for early detection of lung cancer and abolishing pulmonary metastasis: Critical appraisal of newer developments and challenges to clinical transition
Gao, X., Guo, L., Li, J., Thu, H. E., & Hussain, Z. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.024 · Cited by 62
Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology
Glimelius, B. L. G., & Lahn, M. M. F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq622 · Cited by 64
Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
Jiang, W., Cai, G., Hu, P. C., & Wang, Y. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.04.005 · Cited by 67
Should we continue to use the term non-small-cell lung cancer?
Gazdar, A. F. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq372 · Cited by 62
Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non–Small-Cell Lung Cancer
Sjøblom, B., Benth, J. Š., Grønberg, B. H., Baracos, V. E., Sawyer, M. B., Fløtten, Ø., Hjermstad, M. J., Aass, N., & Jordhøy, M. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.09.008 · Cited by 62
Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis
Botrel, T. E. A., Clark, O. A. C., Clark, L. G., Paladini, L. M., Faleiros, E., & Pegoretti, B. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.028 · Cited by 62
Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review
Chen, X., Liu, Y., Røe, O. D., Qian, Y., Guo, R., Zhu, L., Yin, Y., & Shu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059314 · Cited by 62
HMGB1 Protein
Ugrinova, I., & Pasheva, E. A. (2016) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2016.10.001 · Cited by 63
Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: A single-institution study
Agemi, Y., Shimokawa, T., Sasaki, J., Miyazaki, K., Misumi, Y., Sato, A., Aida, S., Ishii, M., Nakamura, Y., Naoki, K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210499 · Cited by 62
Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy
Moon, S. H., Cho, S.-H., Park, L. C., Ji, J. H., Sun, J., Ahn, J. S., Park, K., Choi, J. Y., & Ahn, M. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2400-4 · Cited by 60
Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients
Tibaldi, C., Giovannetti, E., Tiseo, M., León, L. G., D’Incecco, A., Losekoot, N., Bartolotti, M., Honeywell, R. J., Cappuzzo, F., Ardizzoni, A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr280 · Cited by 60
Outcomes After Combined Modality Therapy forEGFR-Mutant and Wild-Type Locally Advanced NSCLC
Mak, R. H., Doran, E., Muzikansky, A., Kang, J., Neal, J. W., Choi, N. C., Willers, H., Jackman, D. M., & Sequist, L. V. D. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0040 · Cited by 59
Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer.
Isobe, K., Hata, Y., Kobayashi, K., Hirota, N., Sato, K., Sano, G., Sugino, K., Sakamoto, S., Takai, Y., Shibuya, K., et al. (2012) · PubMed · Cited by 59
Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial
Nicolson, M. C., Fennell, D. A., Ferry, D. R., O'Byrne, K. J., Shah, R. N. H., Potter, V. A., Skailes, G., Upadhyay, S., Taylor, P. D., André, V., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318292c500 · Cited by 59
Exercise and Nutrition Interventions in Advanced Lung Cancer: A Systematic Review
Payne, C., Larkin, P. J., McIlfatrick, S., Dunwoody, L., & Gracey, J. (2013) · Current Oncology · doi:10.3747/co.20.1431 · Cited by 62
Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease
Campos-Parra, A. D., Avilés, A., Contreras-Reyes, S., Rojas-Marín, C. E., Sánchez-Reyes, R., Borbolla-Escoboza, R. J., & Arrieta, O. G. (2014) · European Respiratory Journal · doi:10.1183/09031936.00138813 · Cited by 59
The multiple cellular functions of the oncoprotein Golgi phosphoprotein 3
Sechi, S., Frappaolo, A., Belloni, G., Colotti, G., & Giansanti, M. G. (2015) · Oncotarget · doi:10.18632/oncotarget.3051 · Cited by 58
Continuous sc infusion of narcotics using a portable disposable device in patients with advanced cancer.
Bruera, E. D., Brenneis, C., Michaud, M., Chadwick, S., & MacDonald, R. N. (1987) · PubMed · Cited by 59
A Phase I Trial and in vitro Studies Combining ABT-751 with Carboplatin in Previously Treated Non-Small Cell Lung Cancer Patients
Ma, T., Fuld, A. D., Rigas, J. R., Hagey, A. E., Gordon, G., Dmitrovsky, E., & Dragnev, K. H. (2012) · Chemotherapy · doi:10.1159/000343165 · Cited by 58
Chemotherapy for Advanced-Stage Non–Small Cell Lung Cancer
Du, L., & Morgensztern, D. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000141 · Cited by 58
Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non-small Cell Lung Cancer Patients Aged 70 Years or Older
Chen, Y.-M., Tsai, C., Fan, W.-C., Shih, J.-F., Liu, S.-H., Wu, C.-H., Chou, T., Lee, Y.-C., Perng, R.-P., & Whang‐Peng, J. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823a39e8 · Cited by 57
Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC
Lewintre, E. J., Sanmartín, E., Sirera, R., Blasco, A., Sánchez, J. J., Tarón, M., Rosell, R., & Camps, C. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.016 · Cited by 57
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
Ramalingam, S. S., Crawford, J., Chang, A. Y., Manegold, C., Perez-Soler, R., Douillard, J.-Y., Thatcher, N., Barlési, F., Owonikoko, T. K., Wang, Y., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt371 · Cited by 57
Self-citation
Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy
Bradbury, P. A., Morris, D. G., Nicholas, G. A., Tu, D., Tehfe, M., Goffin, J. R., Shepherd, F. A., Gregg, R. W., Rothenstein, J. M., Lee, C., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.03.005 · Cited by 57
Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Gridelli, C., de Marinis, F., Pujol, J.-L., Reck, M., Ramlau, R., Parente, B., Pieters, T., Middleton, G., Corral, J., Winfree, K. B., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318267cf84 · Cited by 58
Cisplatin versus Carboplatin-Based Regimens for the Treatment of Patients with Metastatic Lung Cancer. An Analysis of Veterans Health Administration Data
Santana-Dávila, R., Szabó, A., Arce-Lara, C. E., Williams, C. D., Kelley, M. J., & Whittle, J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000146 · Cited by 56
Treatment Monitoring Program for Implementation of Adherence to Second-Line Erlotinib for Advanced Non–Small-Cell Lung Cancer
Gebbia, V., Bellavia, M., Banna, G. L., Russo, P., Ferraù, F., Tralongo, P., & Borsellino, N. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.11.007 · Cited by 55
Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer
Coate, L. E., Massey, C., Hope, A. J., Sacher, A. G., Barrett, K., Pierre, A. F., Leighl, N. B., Brade, A. M., de Perrot, M. E., Waddell, T. K., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820b8b9b · Cited by 55
Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma
Tamura, Y., Fujiwara, Y., Yamamoto, N., Nokihara, H., Horinouchi, H., Kanda, S., Goto, Y., Kubo, E., Kitahara, S., Tsuruoka, K., et al. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1762-z · Cited by 55
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study
Morabito, A., Gebbia, V., Di Maio, M., Cinieri, S., Viganò, M. G., Bianco, R., Barbera, S., Cavanna, L., De Marinis, F., Montesarchio, V., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.04.008 · Cited by 53
Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study
Gridelli, C., de Marinis, F., Thomas, M., Prabhash, K., Kouri, C. E., Blackhall, F. H., Bustin, F., Pujol, J.-L., John, W. J., Antonio, B. S., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000207 · Cited by 54
The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease
Shimizu, R., Fujimoto, D., Kato, R., Otoshi, T., Kawamura, T., Tamai, K., Matsumoto, T., Nagata, K., Otsuka, K., Nakagawa, A., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2590-x · Cited by 54
Iron-catalyzed cascade reaction of 2-aminobenzyl alcohols with benzylamines: synthesis of quinazolines by trapping of ammonia
Gopalaiah, K., Saini, A., & Devi, A. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob01159h · Cited by 54
Added value of molecular targeted agents in oncology
Soria, J., Blay, J., Spano, J., Pivot, X. B., Coscas, Y., & Khayat, D. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq675 · Cited by 53
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer
Thomas, M., Sadjadian, P., Kollmeier, J., Lowe, J. R., Mattson, P., Trout, J. R., Gargano, M. A., Patchen, M. L., Walsh, R. M., Béliveau, M., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0450-3 · Cited by 53
Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial
Ardizzoni, A., Tiseo, M., Boni, L., Vincent, A. D., Passalacqua, R., Buti, S., AMOROSO, D., Camerini, A., Labianca, R., Genestreti, G., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.6758 · Cited by 52
CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study
Li, H., Zhang, R., Wang, S., Fang, M., Zhu, Y., Hu, Z., Dong, D., Shi, J., & Tian, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00057 · Cited by 52
Interactions Between Cytotoxic Chemotherapy and Antiretroviral Treatment in Human Immunodeficiency Virus-Infected Patients with Lung Cancer
Makinson, A., Pujol, J.-L., Moing, V. L., Peyrière, H., & Reynes, J. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d3ccf2 · Cited by 52
A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non–Small-Cell Lung Cancer
Stinchcombe, T. E., Roder, J., Peterman, A. H., Grigorieva, J., Lee, C. B., Moore, D. T., & Socinski, M. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182835577 · Cited by 51
Survival among non-small cell lung cancer patients with poor performance status after first line chemotherapy
Salloum, R. G., Smith, T. J., Jensen, G. A., & Lafata, J. E. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.04.019 · Cited by 51
Self-citation
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
Tiseo, M. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6594 · Cited by 51
Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial
Wang, J., Lu, S., Yu, X., Hu, Y., Zhao, J., Sun, M., Yu, Y., Hu, C., Yang, K., Song, Y., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103727 · Cited by 54
Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study
Rengan, R., Mitra, N., Liao, K., Armstrong, K., & Vachani, A. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70466-7 · Cited by 50
Human Immunodeficiency Virus Infection and Non-small Cell Lung Cancer: Survival and Toxicity of Antineoplastic Chemotherapy in a Cohort Study
Makinson, A., Tenon, J.-C., Eymard‐Duvernay, S., Pujol, J.-L., Allavena, C., Cuzin, L., Poizot‐Martin, I., Tribonnière, X. D. L., Cabie, A., Puglièse, P., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318217b6e0 · Cited by 50
Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Lung Adenocarcinoma: Results of a Nagano Lung Cancer Research Group Study
Asami, K., Koizumi, T., Hirai, K., Ameshima, S., Tsukadaira, A., Morozumi, N., Morikawa, A., Atagi, S., & Kawahara, M. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.02.004 · Cited by 49
FrequentEGFRmutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis
Wu, S., Hu, F., Chang, Y., Lee, Y.-C., Yu, C., Chang, Y., Wu, J., Shih, J., & Yang, P. (2012) · European Respiratory Journal · doi:10.1183/09031936.00006912 · Cited by 49
Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients
Liu, C., Huang, Y.-S., Chen, Y., Li-Xu, Y., Xin-lan, L., Luo, D., Chen, J., Yi-lon, W., & Hui, L. Y. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.08.018 · Cited by 48
Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance
Ma, Q., Li, P., Xu, M., Yin, J., Su, Z., Li, W., & Zhang, J. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-99 · Cited by 48
Dacomitinib, a new therapy for the treatment of non-small cell lung cancer
Brzezniak, C. E., Carter, C. A., & Giaccone, G. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.758714 · Cited by 48
Self-citation
Using claims‐based measures to predict performance status score in patients with lung cancer
Salloum, R. G., Smith, T. J., Jensen, G. A., & Lafata, J. E. (2010) · Cancer · doi:10.1002/cncr.25677 · Cited by 48
Self-citation

Authors: Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., Nordquist, L., Pfister, D. G., Piantadosi, S., Schiller, J. H., Smith, R., Smith, T. J., Strawn, J. R., Trent, D., & Giaccone, G.
Affiliations: American Society of Clinical Oncology (US)
ORCID: Azzoli, Christopher G.
Temin, Sarah
Pao, William
Brahmer, Julie
Johnson, David H.
Masters, Gregory
Pfister, David G.
Piantadosi, Steven
Schiller, Joan H.
Smith, Thomas J.
Giaccone, Giuseppe
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-12-20
Volume: 27
Issue: 36
Pages: 6251-6266
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.23.5622
PMC: PMC2793036
OpenAlex: W2119366998
Cited by: 915
References: 218
Citations by year: 2026: 6 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 25 · 2020: 21 · 2019: 33 · 2018: 38 · 2017: 38 · 2016: 67 · 2015: 89 · 2014: 111 · 2013: 128 · 2012: 119
FWCI: 90.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: stage IV non-small cell lung cancer, chemotherapy, first-line therapy, second-line therapy, third-line therapy, gefitinib, erlotinib, bevacizumab, carboplatin-paclitaxel, cetuximab, docetaxel, EGFR mutation, platinum-based doublets, overall survival, progression-free survival, treatment toxicity
MeSH terms: Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Staging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks